nach oben

Osteoporosis International

Erschienen in:

05.08.2016 | Review

Osteogenesis imperfecta in children and adolescents—new developments in diagnosis and treatment

verfasst von: P. Trejo, F. Rauch

Erschienen in: Osteoporosis International | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Osteogenesis imperfecta (OI) is the most prevalent heritable bone fragility disorder in children. It has been known for three decades that the majority of individuals with OI have mutations in COL1A1 or COL1A2, the two genes coding for collagen type I alpha chains, but in the past 10 years defects in at least 17 other genes have been linked to OI. Almost all individuals with a typical OI phenotype have a mutation in one of the currently known genes. Regarding medical treatment, intravenous bisphosphonate therapy is the most widely used medical approach. This has a marked effect on vertebra in growing children and can lead to vertebral reshaping after compression fractures, but there is little effect of bisphosphonate therapy on the development of scoliosis. Bisphosphonate treatment decreases long-bone fracture rates, but such fractures are still frequent. Newer medications with anti-resorptive and bone anabolic action are being investigated in an attempt to improve on the efficacy of bisphosphonates but the safety and efficacy of these new approaches in children with OI is not yet established.

Forlino A, Marini JC (2016) Osteogenesis imperfecta. Lancet 387:1657–1671CrossRefPubMed

Hendrickx G, Boudin E, Van Hul W (2015) A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat Rev Rheumatol 11:462–474CrossRefPubMed

Rivadeneira F, Makitie O (2016) Osteoporosis and bone mass disorders: from gene pathways to treatments. Trends Endocrinol Metab 27:262–281CrossRefPubMed

Biggin A, Munns CF (2014) Osteogenesis imperfecta: diagnosis and treatment. Curr Osteoporos Rep 12:279–288CrossRefPubMed

Harrington J, Sochett E, Howard A (2014) Update on the evaluation and treatment of osteogenesis imperfecta. Pediatr Clin North Am 61:1243–1257CrossRefPubMed

Hoyer-Kuhn H, Netzer C, Semler O (2015) Osteogenesis imperfecta: pathophysiology and treatment. Wien Med Wochenschr 165:278–284CrossRefPubMed

Shaker JL, Albert C, Fritz J, Harris G (2015) Recent developments in osteogenesis imperfecta. F1000Res 4:681

Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101–116CrossRefPubMedPubMedCentral

Bonafe L, Cormier-Daire V, Hall C et al (2015) Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A 167A:2869–2892CrossRefPubMed

10.

Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377–1385CrossRefPubMed

11.

Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R (2002) Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17:30–38CrossRefPubMed

12.

Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ, Glorieux FH (2002) Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 31:12–18CrossRefPubMed

13.

Van Dijk FS, Sillence DO (2014) Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A 164A:1470–1481CrossRefPubMed

14.

Bonadio J, Holbrook KA, Gelinas RE, Jacob J, Byers PH (1985) Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta. J Biol Chem 260:1734–1742PubMed

15.

Lindahl K, Astrom E, Rubin CJ, Grigelioniene G, Malmgren B, Ljunggren O, Kindmark A (2015) Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet 23:1042–1050CrossRefPubMedPubMedCentral

16.

Bronicki LM, Stevenson RE, Spranger JW (2015) Beyond osteogenesis imperfecta: causes of fractures during infancy and childhood. Am J Med Genet C: Semin Med Genet 169:314–327CrossRef

17.

Pepin MG, Byers PH (2015) What every clinical geneticist should know about testing for osteogenesis imperfecta in suspected child abuse cases. Am J Med Genet C: Semin Med Genet 169:307–313CrossRef

18.

Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Genotype-phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I. Eur J Hum Genet 18:642–647CrossRefPubMedPubMedCentral

19.

Valadares ER, Carneiro TB, Santos PM, Oliveira AC, Zabel B (2014) What is new in genetics and osteogenesis imperfecta classification? J Pediatr (Rio J) 90:536–541CrossRef

20.

Willing MC, Deschenes SP, Scott DA, Byers PH, Slayton RL, Pitts SH, Arikat H, Roberts EJ (1994) Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen. Am J Hum Genet 55:638–647PubMedPubMedCentral

21.

Schleit J, Bailey SS, Tran T, Chen D, Stowers S, Schwarze U, Byers PH (2015) Molecular outcome, prediction, and clinical consequences of splice variants in COL1A1, which encodes the proalpha1(I) chains of type I procollagen. Hum Mutat 36:728–739CrossRefPubMed

22.

Bardai G, Lemyre E, Moffatt P, Palomo T, Glorieux FH, Tung J, Ward L, Rauch F (2016) Osteogenesis imperfecta type I caused by COL1A1 deletions. Calcif Tissue Int 98:76–84CrossRefPubMed

23.

Ben Amor IM, Roughley P, Glorieux FH, Rauch F (2013) Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. J Bone Miner Res 28:2001–2007CrossRefPubMed

24.

Cabral WA, Makareeva E, Colige A, Letocha AD, Ty JM, Yeowell HN, Pals G, Leikin S, Marini JC (2005) Mutations near amino end of alpha1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing. J Biol Chem 280:19259–19269CrossRefPubMed

25.

Marini JC, Forlino A, Cabral WA et al (2007) Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 28:209–221CrossRefPubMedPubMedCentral

26.

Fahiminiya S, Al-Jallad H, Majewski J, Palomo T, Moffatt P, Roschger P, Klaushofer K, Glorieux FH, Rauch F (2015) A polyadenylation site variant causes transcript-specific BMP1 deficiency and frequent fractures in children. Hum Mol Genet 24:516–524CrossRefPubMed

27.

van Dijk FS, Zillikens MC, Micha D et al (2013) PLS3 mutations in X-linked osteoporosis with fractures. N Engl J Med 369:1529–1536CrossRefPubMed

28.

Zarate YA, Clingenpeel R, Sellars EA, Tang X, Kaylor JA, Bosanko K, Linam LE, Byers PH (2016) COL1A1 and COL1A2 sequencing results in cohort of patients undergoing evaluation for potential child abuse. Am J Med Genet A

29.

Rauch F, Moffatt P, Cheung M, Roughley P, Lalic L, Lund AM, Ramirez N, Fahiminiya S, Majewski J, Glorieux FH (2013) Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C>T mutation in all patients. J Med Genet 50:21–24CrossRefPubMed

30.

Grover M, Campeau PM, Lietman CD, Lu JT, Gibbs RA, Schlesinger AE, Lee BH (2013) Osteogenesis imperfecta without features of type V caused by a mutation in the IFITM5 gene. J Bone Miner Res 28:2333–2337CrossRefPubMedPubMedCentral

31.

Cheung MS, Glorieux FH, Rauch F (2007) Natural history of hyperplastic callus formation in osteogenesis imperfecta type V. J Bone Miner Res 22:1181–1186CrossRefPubMed

32.

Fassier AM, Rauch F, Aarabi M, Janelle C, Fassier F (2007) Radial head dislocation and subluxation in osteogenesis imperfecta. J Bone Joint Surg Am 89:2694–2704CrossRefPubMed

33.

Cheung MS, Arponen H, Roughley P, Azouz ME, Glorieux FH, Waltimo-Siren J, Rauch F (2011) Cranial base abnormalities in osteogenesis imperfecta: phenotypic and genotypic determinants. J Bone Miner Res 26:405–413CrossRefPubMed

34.

Faqeih E, Roughley P, Glorieux FH, Rauch F (2009) Osteogenesis imperfecta type III with intracranial hemorrhage and brachydactyly associated with mutations in exon 49 of COL1A2. Am J Med Genet A 149A:461–465CrossRefPubMed

35.

Kishta W, Abduljabbar FH, Gdalevitch M, Rauch F, Hamdy R, Fassier F (2015) Hip dysplasia in children with osteogenesis imperfecta: association with collagen type I C-propeptide mutations. J Pediatr Orthop

36.

Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E (2012) First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 12:183–188PubMed

37.

Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O (2014) Two years’ experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis 9:145CrossRefPubMedPubMedCentral

38.

Sule G, Campeau PM, Zhang VW et al (2013) Next-generation sequencing for disorders of low and high bone mineral density. Osteoporos Int 24:2253–2259CrossRefPubMedPubMedCentral

39.

Rauch F, Lalic L, Glorieux FH, Moffatt P, Roughley P (2014) Targeted sequencing of a pediatric metabolic bone gene panel using a desktop semiconductor next-generation sequencer. Calcif Tissue Int 95:323–331CrossRefPubMed

40.

Bardai G, Moffatt P, Glorieux FH, Rauch F DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum..Osteoporos Int. In press

41.

Pouliot-Laforte A, Veilleux LN, Rauch F, Lemay M (2015) Physical activity in youth with osteogenesis imperfecta type I. J Musculoskelet Neuronal Interact 15:171–176PubMed

42.

Glorieux FH (2007) Treatment of osteogenesis imperfecta: who, why, what? Horm Res 68(Suppl 5):8–11PubMed

43.

Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Soderhall S, Ljunggren O, Astrom E (2016) Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with pamidronate. Bone 87:11–18CrossRefPubMed

44.

Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, Engelbert RH, Sillence DO, Munns CF (2013) Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr 79:333–340CrossRefPubMed

45.

Saraff V, Hogler W (2015) Osteoporosis in children: diagnosis and management. Eur J Endocrinol 173:R185–R197CrossRefPubMed

46.

Thomas IH, DiMeglio LA (2016) Advances in the classification and treatment of osteogenesis imperfecta. Curr Osteoporos Rep 14:1–9CrossRefPubMed

47.

Edouard T, Glorieux FH, Rauch F (2011) Relationship between vitamin D status and bone mineralization, mass, and metabolism in children with osteogenesis imperfecta: histomorphometric study. J Bone Miner Res 26:2245–2251CrossRefPubMed

48.

Edouard T, Glorieux FH, Rauch F (2011) Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta. J Clin Endocrinol Metab 96:3193–3198CrossRefPubMed

49.

Zambrano MB, Brizola E, Pinheiro B, Vanz AP, Mello ED, Felix TM (2016) Study of the determinants of vitamin D status in pediatric patients with osteogenesis imperfecta. J Am Coll Nutr 35:339–345CrossRefPubMed

50.

Plante L, Veilleux LN, Glorieux FH, Weiler H, Rauch F (2016) Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: a randomized controlled trial. Bone 86:36–42CrossRefPubMed

51.

Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360–363CrossRefPubMed

52.

Dwan K, Phillipi CA, Steiner RD, Basel D (2014) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 7:Cd005088

53.

Hald JD, Evangelou E, Langdahl BL, Ralston SH (2015) Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res 30:929–933CrossRefPubMed

54.

Rijks EB, Bongers BC, Vlemmix MJ, Boot AM, van Dijk AT, Sakkers RJ, van Brussel M (2015) Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review. Horm Res Paediatr 84:26–42CrossRefPubMed

55.

Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res 25:1367–1374PubMed

56.

Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293–1299CrossRefPubMedPubMedCentral

57.

Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH (2006) Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 39:901–906CrossRefPubMed

58.

Semler O, Beccard R, Palmisano D, Demant A, Fricke O, Schoenau E, Koerber F (2011) Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta. Horm Res Paediatr 76:321–327CrossRefPubMed

59.

Astrom E, Jorulf H, Soderhall S (2007) Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child 92:332–338CrossRefPubMed

60.

Astrom E, Soderhall S (2002) Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86:356–364CrossRefPubMedPubMedCentral

61.

Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F (2015) Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res 30:2150–2157CrossRefPubMed

62.

Bishop N, Adami S, Ahmed SF et al (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 382:1424–1432CrossRefPubMed

63.

Ward LM, Rauch F, Whyte MP et al (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 96:355–364CrossRefPubMed

64.

Sato A, Ouellet J, Muneta T, Glorieux FH, Rauch F (2016) Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations—genotype-phenotype correlations and effect of bisphosphonate treatment. Bone 86:53–57CrossRefPubMed

65.

Anissipour AK, Hammerberg KW, Caudill A, Kostiuk T, Tarima S, Zhao HS, Krzak JJ, Smith PA (2014) Behavior of scoliosis during growth in children with osteogenesis imperfecta. J Bone Joint Surg Am 96:237–243CrossRefPubMed

66.

Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427–1431CrossRefPubMed

67.

Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952CrossRefPubMed

68.

Palomo T, Glorieux FH, Schoenau E, Rauch F (2016) Body composition in children and adolescents with osteogenesis imperfecta. J Pediatr 169:232–237CrossRefPubMed

69.

Rauch F, Land C, Cornibert S, Schoenau E, Glorieux FH (2005) High and low density in the same bone: a study on children and adolescents with mild osteogenesis imperfecta. Bone 37:634–641CrossRefPubMed

70.

Albert C, Jameson J, Smith P, Harris G (2014) Reduced diaphyseal strength associated with high intracortical vascular porosity within long bones of children with osteogenesis imperfecta. Bone 66:121–130CrossRefPubMedPubMedCentral

71.

Weber M, Roschger P, Fratzl-Zelman N, Schoberl T, Rauch F, Glorieux FH, Fratzl P, Klaushofer K (2006) Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 39:616–622CrossRefPubMed

72.

Montpetit K, Palomo T, Glorieux FH, Fassier F, Rauch F (2015) Multidisciplinary treatment of severe osteogenesis imperfecta: functional outcomes at skeletal maturity. Arch Phys Med Rehabil 96:1834–1839CrossRefPubMed

73.

Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD (2004) Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy 24:195–197CrossRefPubMed

74.

Li M, Xia WB, Xing XP et al (2011) Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta. Chin Med J (Engl) 124:3049–3053

75.

Munns CF, Rajab MH, Hong J, Briody J, Hogler W, McQuade M, Little DG, Cowell CT (2007) Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 41:366–370CrossRefPubMed

76.

George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA (2015) Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience. J Clin Endocrinol Metab 100:4163–4171CrossRefPubMedPubMedCentral

77.

Kumar C, Panigrahi I, Somasekhara Aradhya A, Meena BL, Khandelwal N (2016) Zoledronate for osteogenesis imperfecta: evaluation of safety profile in children. J Pediatr Endocrinol Metab

78.

Trivedi S, Al-Nofal A, Kumar S, Tripathi S, Kahoud RJ, Tebben PJ (2016) Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child. Osteoporos Int

79.

Munns CF, Rauch F, Mier RJ, Glorieux FH (2004) Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 35:231–234CrossRefPubMed

80.

Olson JA (2014) Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report. J Pediatr Rehabil Med 7:155–158PubMed

81.

Hennedige AA, Jayasinghe J, Khajeh J, Macfarlane TV (2013) Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J Oral Maxillofac Res 4:e1CrossRefPubMed

82.

Bhatt RN, Hibbert SA, Munns CF (2014) The use of bisphosphonates in children: review of the literature and guidelines for dental management. Aust Dent J 59:9–19CrossRefPubMed

83.

Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19:1779–1786CrossRefPubMed

84.

Anam EA, Rauch F, Glorieux FH, Fassier F, Hamdy R (2015) Osteotomy healing in children with osteogenesis imperfecta receiving bisphosphonate treatment. J Bone Miner Res 30:1362–1368CrossRefPubMed

85.

Meier RP, Ing Lorenzini K, Uebelhart B, Stern R, Peter RE, Rizzoli R (2012) Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta—a case report. Acta Orthop 83:548–550CrossRefPubMedPubMedCentral

86.

Manolopoulos KN, West A, Gittoes N (2013) The paradox of prevention—bilateral atypical subtrochanteric fractures due to bisphosphonates in osteogenesis imperfecta. J Clin Endocrinol Metab 98:871–872CrossRefPubMed

87.

Holm J, Eiken P, Hyldstrup L, Jensen JE (2014) Atypical femoral fracture in an osteogenesis imperfecta patient successfully treated with teriparatide. Endocr Pract 20:e187–e190CrossRefPubMed

88.

Etxebarria-Foronda I, Carpintero P (2015) An atypical fracture in male patient with osteogenesis imperfecta. Clin Cases Miner Bone Metab 12:278–281PubMedPubMedCentral

89.

Vasanwala RF, Sanghrajka A, Bishop NJ, Hogler W (2016) Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating? J Bone Miner Res

90.

Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23CrossRefPubMed

91.

Dent JA, Paterson CR (1991) Fractures in early childhood: osteogenesis imperfecta or child abuse? J Pediatr Orthop 11:184–186CrossRefPubMed

92.

Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, Hero B, Schoenau E, Semler O (2016) Safety and efficacy of denosumab in children with osteogenesis imperfecta—a first prospective trial. J Musculoskelet Neuronal Interact 16:24–32PubMed

93.

Wang HD, Boyce AM, Tsai JY, Gafni RI, Farley FA, Kasa-Vubu JZ, Molinolo AA, Collins MT (2014) Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab 99:891–897CrossRefPubMedPubMedCentral

94.

Rauch F, Travers R, Munns C, Glorieux FH (2004) Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 19:1191–1193CrossRefPubMed

95.

Boyce AM, Chong WH, Yao J et al (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 27:1462–1470CrossRefPubMedPubMedCentral

96.

Setsu N, Kobayashi E, Asano N, Yasui N, Kawamoto H, Kawai A, Horiuchi K (2016) Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab 34:118–122CrossRefPubMed

97.

Orwoll ES, Shapiro J, Veith S et al (2014) Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 124:491–498CrossRefPubMedPubMedCentral

98.

Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM (2013) Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res 28:73–80CrossRefPubMedPubMedCentral

99.

Jacobsen CM, Barber LA, Ayturk UM et al (2014) Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. J Bone Miner Res 29:2297–2306CrossRefPubMedPubMedCentral

100.

Grafe I, Alexander S, Yang T et al (2016) Sclerostin antibody treatment improves the bone phenotype of Crtap(−/−) mice, a model of recessive osteogenesis imperfecta. J Bone Miner Res 31:1030–1040CrossRefPubMed

101.

Roschger A, Roschger P, Keplingter P, Klaushofer K, Abdullah S, Kneissel M, Rauch F (2014) Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone 66:182–188CrossRefPubMed

102.

Rauch F, Travers R, Parfitt AM, Glorieux FH (2000) Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26:581–589CrossRefPubMed

103.

Reid IR (2015) Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol 11:418–428CrossRefPubMed

104.

Tosi LL, Oetgen ME, Floor MK et al (2015) Initial report of the osteogenesis imperfecta adult natural history initiative. Orphanet J Rare Dis 10:146CrossRefPubMedPubMedCentral

105.

Yimgang DP, Shapiro JR (2016) Pregnancy outcomes in women with osteogenesis imperfecta. J Matern Fetal Neonatal Med 29:2358–2362CrossRefPubMed

106.

Patel RM, Nagamani SC, Cuthbertson D et al (2015) A cross-sectional multicenter study of osteogenesis imperfecta in North America—results from the linked clinical research centers. Clin Genet 87:133–140CrossRefPubMed

107.

Rauch F, Munns C, Land C, Glorieux FH (2006) Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 91:1268–1274CrossRefPubMed

Titel: Osteogenesis imperfecta in children and adolescents—new developments in diagnosis and treatment
verfasst von: P. Trejo
F. Rauch
Publikationsdatum: 05.08.2016
Verlag: Springer London
Erschienen in: Osteoporosis International / Ausgabe 12/2016
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-016-3723-3

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

Skeletal outcomes by peripheral quantitative computed tomography and dual-energy X-ray absorptiometry in adolescent girls with anorexia nervosa

Visceral fat measured by DXA is associated with increased risk of non-spine fractures in nonobese elderly women: a population-based prospective cohort analysis from the São Paulo Ageing & Health (SPAH) Study

Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury

Health-related quality of life in older people with osteoporotic vertebral fractures: clinically important vs. statistically significant

Effects of doxorubicin administration on bone strength and quality in sedentary and physically active Wistar rats